文献速递炎症性肠病

IBD母亲宫内暴露于硫嘌呤和抗TNF药物所生儿童严重感染风险

Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-07-21

基于法国全国健康数据库2010–2018年26,561名IBD母亲所生儿童,采用倾向评分加权边际Cox模型比较宫内暴露于硫嘌呤和/或抗TNF药物与未暴露儿童的严重感染风险。硫嘌呤单药(aHR 0.94;95%CI 0.83-1.07)和抗TNF单药(aHR 1.10;95%CI 0.95-1.27)第一年严重感染风险与未暴露相似,联合治疗风险升高(aHR 1.36;95%CI 1.04-1.79);第2–5年风险与治疗无关。

要点

  • 硫嘌呤或抗TNF单药宫内暴露不增加儿童5年内严重感染风险
  • 联合治疗与第一年严重感染风险升高相关(aHR 1.36;95%CI 1.04-1.79)
  • 最高风险见于神经系统感染和病毒感染,第2–5年无治疗相关风险

核心结论

  • IBD母亲宫内暴露于硫嘌呤和抗TNF单药不增加儿童出生后5年内严重感染风险。
  • 联合治疗与儿童出生后第一年严重感染风险升高相关。

研究设计与样本

  • 基于法国全国健康数据库(覆盖99%法国人口,约66,000,000人)的回顾性队列研究。
  • 纳入2010–2018年法国IBD女性所生活产儿,共26,561名儿童。
  • 采用倾向评分加权边际Cox模型比较儿童出生后5年内严重感染风险。

主要发现

  • 硫嘌呤单药暴露组3,392名,抗TNF单药暴露组3,399名,联合治疗组816名,未暴露组18,954名。
  • 第一年严重感染风险:硫嘌呤单药aHR 0.94(95%CI 0.83-1.07),抗TNF单药aHR 1.10(95%CI 0.95-1.27),与未暴露组相似。
  • 联合治疗组第一年严重感染风险升高:aHR 1.36(95%CI 1.04-1.79)。
  • 风险升高最明显的是神经系统感染和病毒感染。
  • 出生后第2–5年严重感染风险与IBD治疗无关。

临床怎么用

  • IBD妊娠女性使用硫嘌呤或抗TNF单药时,无需因儿童严重感染风险而调整治疗。
  • 使用联合治疗需权衡第一年严重感染风险升高(aHR 1.36;95%CI 1.04-1.79),尤其关注神经系统和病毒感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We aimed to compare the risk of serious infections in children with in utero exposure to thiopurines and/or anti-tumor necrosis factor (TNF) born to mothers with inflammatory bowel disease (IBD). METHODS: Using the French national health database, which covers 99% of the French population (around 66,000,000 people), we identified live births among women with IBD in France between 2010 and 2018. The risks of serious infections in children during the first 5 years of life were compared according to treatment exposures during pregnancy using propensity score-weighted marginal Cox models. RESULTS: A total of 26,561 children were included: 3392 were exposed to thiopurine monotherapy, 3399 to anti-TNF monotherapy, 816 to combination therapy, and 18,954 were not exposed to any of these drugs. The risks of serious infections during the first year of life among children exposed to thiopurine monotherapy (adjusted hazard ratio [aHR], 0.94; 95% confidence interval [CI], 0.83-1.07) and anti-TNF monotherapy (aHR, 1.10; 95% CI, 0.95-1.27) were similar to those of unexposed children; a higher risk was observed in children exposed to combination therapy (aHR, 1.36; 95% CI, 1.04-1.79). The highest increased risks were observed for nervous system infections and viral infections. The risk of serious infections during the second to fifth years of life was not associated with IBD treatments. CONCLUSIONS: In children born to mothers with IBD, in utero exposure to thiopurine and anti-TNF monotherapies do not increase the risk of serious infections during the first 5 years of life. Combination therapy is associated with an increased risk of serious infections during the first year of life.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Meyer A, Taine M, Drouin J, et al. Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor. Clin Gastroenterol Hepatol. 2021. PMID: 34298191. doi:10.1016/j.cgh.2021.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。